Urinary antihypertensive drug metabolite screening using molecular networking coupled to high-resolution mass spectrometry fragmentation

Metabolomics

Volumn 12, Issue 7, 2016, Pages

  van der Hooft, Justin J J ^a   Padmanabhan, Sandosh ^a   Burgess, Karl E V ^a   Barrett, Michael P ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Antihypertensive drugs; Drug adherence; Drug metabolism; Fragmentation; High resolution mass spectrometry; Metabolomics; Urine

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BISOPROLOL; CLODIPOGREL; DRUG METABOLITE; IRBESARTAN; LOSARTAN; METFORMIN; PARACETAMOL; RANITIDINE; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; DNA FRAGMENTATION; DRUG METABOLISM; DYNAMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEDICATION COMPLIANCE; METABOLOMICS; MOLECULAR BIOLOGY; SCORING SYSTEM; URINALYSIS; VALIDATION PROCESS;

EID: 84977578096     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-016-1064-z     Document Type: Article

References (41)

1. Bailey, D. G., Malcolm, J., Arnold, O., & DAVID SPENCE, J. (1998). Grapefruit juice–drug interactions. British Journal of Clinical Pharmacology, 46, 101–110.
2. Bantscheff, M., Schirle, M., Sweetman, G., Rick, J., & Kuster, B. (2007). Quantitative mass spectrometry in proteomics: A critical review. Analytical and Bioanalytical Chemistry, 389, 1017–1031.
3. Beresford, A. P., McGibney, D., Humphrey, M. J., Macrae, P. V., & Stopher, D. A. (1988). Metabolism and kinetics of amlodipine in man. Xenobiotica, 18, 245–254.
4. Chace, D. H. (2009). Mass spectrometry in newborn and metabolic screening: Historical perspective and future directions. Journal of Mass Spectrometry, 44, 163–170.
5. Chando, T. J., Everett, D. W., Kahle, A. D., Starrett, A. M., Vachharajani, N., Shyu, W. C., et al. (1998). Biotransformation of irbesartan in man. Drug Metabolism and Disposition, 26, 408–417.
6. Creek, D., Dunn, W., Fiehn, O., Griffin, J., Hall, R., Lei, Z., et al. (2014). Metabolite identification: Are you sure? And how do your peers gauge your confidence? Metabolomics, 10, 350–353.
7. Creek, D. J., Jankevics, A., Breitling, R., Watson, D. G., Barrett, M. P., & Burgess, K. E. V. (2011). Toward global metabolomics analysis with hydrophilic interaction liquid chromatography-mass spectrometry: Improved metabolite identification by retention time prediction. Analytical Chemistry, 83, 8703–8710.
8. da Silva, R. R., Dorrestein, P. C., & Quinn, R. A. (2015). Illuminating the dark matter in metabolomics. Proceedings of the National Academy of Sciences, 112, 12549–12550.
9. Dunn, W. B., Erban, A., Weber, R. M., Creek, D., Brown, M., Breitling, R., et al. (2013). Mass appeal: Metabolite identification in mass spectrometry-focused untargeted metabolomics. Metabolomics, 9, 44–66.
10. Eichelbaum, M., Ende, M., Remberg, G., Schomerus, M., & Dengler, H. J. (1979). The metabolism of DL-[14C]verapamil in man. Drug Metabolism and Disposition, 7, 145–148.
11. Gao, Y., Zhang, R., Bai, J., Xia, X., Chen, Y., Luo, Z., et al. (2015). Targeted data-independent acquisition and mining strategy for trace drug metabolite identification using liquid chromatography coupled with tandem mass spectrometry. Analytical Chemistry, 87, 7535–7539.
12. Garg, N., Kapono, C. A., Lim, Y. W., Koyama, N., Vermeij, M. J. A., Conrad, D., et al. (2015). Mass spectral similarity for untargeted metabolomics data analysis of complex mixtures. International Journal of Mass Spectrometry, 377, 719–727.
13. Horai, H., Arita, M., Kanaya, S., Nihei, Y., Ikeda, T., Suwa, K., et al. (2010). Mass bank: A public repository for sharing mass spectral data for life sciences. Journal of Mass Spectrometry, 45, 703–714.
14. Hufsky, F., Scheubert, K., & Böcker, S. (2014). Computational mass spectrometry for small-molecule fragmentation. TrAC Trends in Analytical Chemistry, 53, 41–48.
15. Kind, T., & Fiehn, O. (2010). Advances in structure elucidation of small molecules using mass spectrometry. Bioanal. Rev., 2, 23–60.
16. Lawson, A. J., Shipman, K. E., George, S., & Dasgupta, I. (2015). A novel ‘dilute-and-shoot’ liquid chromatography-tandem mass spectrometry method for the screening of antihypertensive drugs in urine. Journal of Analytical Toxicology, 40(1), 17–27.
17. Levsen, K., Schiebel, H. M., Behnke, B., Dötzer, R., Dreher, W., Elend, M., & Thiele, H. (2005). Structure elucidation of phase II metabolites by tandem mass spectrometry: An overview. Journal of Chromatography A, 1067, 55–72.
18. Li, L., Li, R., Zhou, J., Zuniga, A., Stanislaus, A. E., Wu, Y., et al. (2013). MycompoundID: Using an evidence-based metabolome library for metabolite identification. Analytical Chemistry, 85, 3401–3408.
19. Lo, M.-W., Goldberg, M. R., McCrea, J. B., Lu, H., Furtek, C. I., & Bjornsson, T. D. (1995). Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clinical Pharmacology and Therapeutics, 58, 641–649.
20. Ma, Y., Kind, T., Yang, D., Leon, C., & Fiehn, O. (2014). MS2analyzer: a software for small molecule substructure annotations from accurate tandem mass spectra. Analytical Chemistry, 86, 10724–10731.
21. Marcum, Z. A., Sevick, M., & Handler, S. M. (2013). Medication nonadherence: A diagnosable and treatable medical condition. JAMA, 309, 2105–2106.
22. McCrea, J. B., Cribb, A., Rushmore, T., Osborne, B., Gillen, L., Lo, M.-W., et al. (1999). Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clinical Pharmacology and Therapeutics, 65, 348–352.
23. Misra, B. B., & van der Hooft, J. J. J. (2016). Updates in metabolomics tools and resources: 2014–2015. Electrophoresis, 37, 86–110.
24. Niessen, W. M. A. (2011). Fragmentation of toxicologically relevant drugs in positive-ion liquid chromatography–tandem mass spectrometry. Mass Spectrometry Reviews, 30, 626–663.
25. Ridder, L., van der Hooft, J. J. J., Verhoeven, S., de Vos, R. C. H., Bino, R. J., & Vervoort, J. (2013). Automatic chemical structure annotation of an LC–MSn based metabolic profile from green tea. Analytical Chemistry, 85, 6033–6040.
26. Ridder, L., van der Hooft, J. J. J., Verhoeven, S., de Vos, R. C. H., Vervoort, J., & Bino, R. J. (2014). In silico prediction and automatic LC–MSN annotation of green tea metabolites in urine. Analytical Chemistry, 86, 4767–4774.
27. Roux, A., Xu, Y., Heilier, J.-F., Olivier, M.-F., Ezan, E., Tabet, J.-C., & Junot, C. (2012). Annotation of the human adult urinary metabolome and metabolite identification using ultra high performance liquid chromatography coupled to a linear quadrupole ion trap-orbitrap mass spectrometer. Analytical Chemistry, 84, 6429–6437.
28. Schmidt, B., & Schieffer, B. (2003). Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. Journal of Medicinal Chemistry, 46, 2261–2270.
29. Suchanova, B., Kostiainen, R., & Ketola, R. A. (2008). Characterization of the in vitro metabolic profile of amlodipine in rat using liquid chromatography–mass spectrometry. European Journal of Pharmaceutical Sciences, 33, 91–99.
30. Suchanova, B., Sispera, L., & Wsol, V. (2006). Liquid chromatography–tandem mass spectrometry in chiral study of amlodipine biotransformation in rat hepatocytes. Analytica Chimica Acta, 573–574, 273–283.
31. Sumner, L. W., Amberg, A., Barrett, D., Beale, M. H., Beger, R., Daykin, C. A., et al. (2007). Proposed minimum reporting standards for chemical analysis. Metabolomics, 3, 211–221.
32. van der Hooft, J. J. J., de Vos, R. C. H., Ridder, L., Vervoort, J., & Bino, R. J. (2013). Structural elucidation of low abundant metabolites in complex sample matrices. Metabolomics, 9, 1009–1018.
33. van der Hooft, J. J. J., Ridder, L., Barrett, M. P., & Burgess, K. E. V. (2015). Enhanced acylcarnitine annotation in (HR-MS) data: fragmentation analysis for the classification and annotation of acylcarnitines. Frontiers in Bioengineering and Biotechnology. doi:10.3389/fbioe.2015.00026.
34. Vinaixa, M., Schymanski, E. L., Neumann, S., Navarro, M., Salek, R. M., & Yanes, O. (2015). Mass spectral databases for LC/MS and GC/MS-based metabolomics: State of the field and future prospects. TrAC Trends in Analytical Chemistry, 78, 23–35.
35. Watrous, J., Roach, P., Alexandrov, T., Heath, B. S., Yang, J. Y., Kersten, R. D., et al. (2012). Mass spectral molecular networking of living microbial colonies. Proceedings of the National Academy of Sciences, 109, E1743–E1752.
36. Wishart, D. S. (2011). Advances in metabolite identification. Bioanalysis, 3, 1769–1782.
37. Yang, J. Y., Sanchez, L. M., Rath, C. M., Liu, X., Boudreau, P. D., Bruns, N., et al. (2013). Molecular networking as a dereplication strategy. Journal of Natural Products, 76, 1686–1699.
38. Zaidenstein, R., Soback, S., Gips, M., Avni, B., Dishi, V., Weissgarten, Y., et al. (2001). Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite e3174 in healthy volunteers. Therapeutic Drug Monitoring, 23, 369–373.
39. Zhang, H., Zhang, D., Ray, K., & Zhu, M. (2009). Mass defect filter technique and its applications to drug metabolite identification by (HR-MS). Journal of Mass Spectrometry, 44, 999–1016.
40. Zhu, M., Ma, L., Zhang, D., Ray, K., Zhao, W., Humphreys, W. G., et al. (2006). Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data. Drug Metabolism and Disposition, 34, 1722–1733.
41. Zubarev, R. A., & Makarov, A. (2013). Orbitrap mass spectrometry. Analytical Chemistry, 85, 5288–5296.